Bronchial thermoplasty increases airway volume measured by functional respiratory imaging

D. Langton1,2*, G. Sloan3, C. Banks1, K. Bennetts1, V. Plummer2 and F. Thien2,4

Abstract

Background: The purpose of this study was to use CT scanning with computational fluid dynamics to evaluate the mechanisms by which Bronchial Thermoplasty (BT) improves asthmatic symptoms.

Methods: The study was conducted in a university teaching hospital, experienced in performing BT. Imaging studies were performed before, and after, BT of the left lung, and prior to treatment of the right lung, which therefore acted as a control. On each occasion, two high-resolution CT scans were performed, one at full inspiration (TLC) and the other at Functional Residual Capacity (FRC). The study protocol was offered to 10 patients, all of whom met the definition of severe asthma, despite high dose inhaled corticosteroids and dual long acting bronchodilators.

Results: Significant increases in airway luminal volume were observed on the treated side, compared with control, at both full inspiration (by 27%) and at FRC (by 17%). The ratio of distal airway volume to lung volume significantly increased on the treated side. The change in airway volume with inspiration from FRC increased by 48% on the treated side compared to 5% in the control lung, suggesting treatment increased airway distensibility. No effect was observed on airway wall thickness, nor air trapping. There was a trend towards correlation between the improvement in airway volume at TLC and improvement in symptoms.

Conclusion: This study demonstrates that BT increases the luminal airway volume on the treated side compared to the control lung. We suggest that this is an important link between the airway smooth muscle atrophy demonstrated pathologically, and the improvement in symptoms observed clinically.

Keywords: Asthma, Bronchial thermoplasty, Airway volume

Summary at a glance

Functional Respiratory Imaging using CT scanning was used to evaluate the effect of bronchial thermoplasty on one lung, whilst the other served as a control. On the treated side, airway luminal volume substantially increased.

Background

Whilst most patients with asthma can expect to be well controlled with inhaled corticosteroids and bronchodilators [1], there remains a small group of patients, estimated to account for 5–10% of adults with asthma, with more refractory, severe disease [2]. These patients have daily symptoms that limit their quality of life, and they have frequent exacerbations which result in lost productivity and increased healthcare utilisation [3]. There are limited therapeutic options for such patients who often find themselves treated with chronic oral steroids with all the attendant steroid related side effects [4]. Hence, there is a need to explore potential alternative treatment options.

Bronchial thermoplasty (BT) is one such option. It was designed to address the known fact that in asthma the airway smooth muscle is hypertrophied [5], and this causes bronchoconstriction and hence wheezing. BT uses a radiofrequency catheter to cause atrophy of this airway smooth muscle [6]. This has been proven to

* Correspondence: davidlangton@phcn.vic.gov.au
1Department of Thoracic Medicine, Frankston Hospital, Peninsula Health, 2 Hastings Road, Frankston, VIC 3199, Australia
2Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic, Australia
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
reduce asthma symptoms and asthma exacerbations in randomised control trials [7–9], but the improvements in lung function which might have been anticipated with such treatment, have either been non-existent [7–9] or modest [10]. Therefore, there is a need to better understand the mechanisms by which this treatment works.

An emerging new field in the evaluation of lung disease is functional imaging, as opposed to purely anatomical imaging [11]. Three techniques exist, namely (i) computerised tomography (CT) (ii) single photon emission computerised tomography (SPECT) and (iii) Magnetic Resonance Imaging (MRI) with a hyperpolarised gas such as helium-3 and xenon-129. Whilst SPECT and MRI provide a detailed evaluation of functional ventilation heterogeneity, they lack the anatomical precision of CT scanning in relation to identification of airway dimensions. A further advantage of using CT scanning is that images can be acquired both at full inspiration and at end expiration, and then computational fluid dynamics can be used to model the dynamic changes in the lung during respiration [12–16].

The purpose of this study was to use CT scanning with computational fluid dynamics to learn more about the mechanisms by which BT improves asthma symptoms, particularly insofar as altering airway and lobar dimensions.

**Method**

**Setting and study design**

This study was conducted in a university teaching hospital with a dedicated severe asthma clinic and five years’ experience in performing BT. The schedule of the BT procedures was altered in a novel way in order to achieve one treated lung (left side) and one untreated lung (right side). The left lower lobe was treated in the first BT session, and then the left upper lobe in the second session. Imaging studies were conducted at baseline, and again four weeks after completion of the left upper lobe BT, and prior to treatment of the right lung (which acted as a control). Following the second set of imaging, the right lower and upper lobes were treated together in the final BT session.

**Participants**

The study protocol was offered to 10 patients with severe asthma who had already chosen to undergo BT. The participants had been thoroughly evaluated and found to meet the ERS/ATS definition of severe asthma [17], despite using substantive asthma therapy including high dose inhaled corticosteroids and dual long acting bronchodilators. Alternative respiratory conditions such as COPD or bronchiectasis had been excluded. All 10 patients had previously been evaluated for monoclonal antibody therapy. Six did not meet Australian funding guidelines (e.g. low eosinophil count), three had previously been treated with omalizumab or mepolizumab, which then had been ceased because of lack of effect, and one patient continued to have severe poorly controlled asthma despite 12 months continuing therapy with mepolizumab. Women of reproductive age who were not using highly effective methods of contraception were excluded from participation so as to avoid radiation exposure to an unborn child.

**Imaging studies**

Non-contrast CT Scanning was performed on a 128-slice Siemens Definition AS+ scanner with a helical slice thickness of 0.6 mm, rotation time of 0.6 s, detector coverage of 38.4 mm, and tube voltage of 100 kV, consistent with the previously published technique for Functional Respiratory Imaging [13]. A typical scan was completed in under 5 s. Two breath-hold scans were performed on each occasion – one at full inspiration, and the other at Functional Residual Capacity (FRC). Immediately prior to the CT scan, the patient was coached in the manoeuvres required for the breath-hold, and a member of the research team was present during the scan, observing the patient from the control room and providing instruction. All imaging was performed in a stable state, pre-bronchodilator, and prior to per-procedural oral steroid administration. The average estimated radiation exposure for each CT scanning session (comprising 2 scans) was 4.6 mSv, or 9.2 mSv radiation exposure for the whole study. A third CT analysis was envisaged after all BT treatment, but at the request of the Ethics Committee this was deferred by 12 months in order to remain within safe annual radiation exposure limits. When available, this data will be presented in a future manuscript.

Post acquisition, CT images were analysed independently to the investigating team by FLUIDDA (Kontich, Belgium). The high-resolution images were imported into Mimics, a commercial, medical imaging processing software package (Materialise, Leuvin, Belgium), which converted the CT images into patient-specific, 3D computer models of the lung lobes and the airway dimensions. Subsequent mathematical modelling was then performed by FLUIDDA, who reported the following parameters for each lobe of each lung: (i) lobar volume (ii) airway volume (iii) airway resistance (iv) airway wall thickness (v) and air trapping.

**Clinical measurements**

The baseline data routinely recorded for all BT patients included age, gender, weight, height, asthma medication usage, asthma exacerbation history, lung function parameters and the asthma quality of life score, the ACQ-5 [18]. Written permission to use the ACQ-5 was provided by the author, Elizabeth Juniper. Patient assessments
were performed by experienced clinical research nursing and scientific staff, and were conducted independently of the procedural team. Spirometry and body plethysmography were performed using the Jaeger Masterscreen Body (Carefusion, Hoechberg, Germany) and tests were conducted in the morning, and having withheld bronchodilators since the previous evening. The laboratory equipment was calibrated on the morning of testing and all tests were conducted to ERS/ATS standards [19]. The predicted value equations used were taken from the Global Lung Initiative [20]. Patient assessments were conducted at baseline, mid–treatment with the left lung treated and right lung untreated, and then at 6 weeks after all treatments were completed.

Safety
All patients undergoing BT at our institution are routinely observed overnight following their procedure. An adverse event is recorded wherever a patient remains in hospital longer than the pre-planned 24 h, or is readmitted to hospital for any reason within 30 days of a BT procedure.

Statistical analysis
SPSS version 25 (IBM corporation, New York, USA) was used for all statistical analyses. Grouped data is reported as mean ± standard deviation, excepting where the data is not normally distributed, in which case median and interquartile range are used. A paired t-test was used to
compare the results for post BT with pre BT, or if there were multiple sets of repeated measured, analysis of variance (ANOVA) was used. Statistical significance was taken at $p < 0.05$ for a two-tailed test.

**Ethics**

Prospective approval to undertake this study was provided by the Peninsula Health Human Research Ethics Committee and no patient was enrolled without having given informed consent.

**Results**

**Baseline characteristics**

Seven females and three males participated, mean age $62.2 \pm 7.7$ years, body mass index $30.6 \pm 6.2$ kg/m$^2$. The mean Forced Expiratory Volume in one second (FEV1) was $42.9 \pm 11.5$% predicted, with an improvement in FEV1 following $400 \mu g$ of salbutamol of $9.6 \pm 9.2$%. The mean forced expiratory ratio was $47.4 \pm 10.7$%. The mean Total Lung Capacity (TLC) was $108.3 \pm 20.7$% predicted, and Residual Volume (RV) was $159 \pm 49$% predicted. The average diffusion capacity for carbon monoxide was $83.3 \pm 32.7$% predicted.

The average ACQ-5 score was $3.4 \pm 1.0$. The median daily requirement for short acting beta-2 agonists was $6.75$ puffs (1,20). Eighty per cent of patients were taking maintenance oral corticosteroids, mean dose $6.7 \pm 7.3$ mg/day. All patients were using dual long acting bronchodilators, as well as inhaled corticosteroids, mean dose $1500 \pm 850 \mu g$/day in beclomethasone equivalence. In the 6 months prior to BT, the average number of exacerbations requiring an increase in oral corticosteroids by more than $10$ mg/day was $2.2 \pm 1.4$. The mean serum eosinophil count was $200 \pm 100$ cells/ul, and the median IgE was $13$ (3,187) IU/ml. Five patients had never smoked and five were former smokers.

**Treatment**

The average number of radiofrequency activations administered to the left lung was $117 \pm 21$, and to the right lung was $82 \pm 23$. In the thirty procedures, on two occasions patients remained in hospital longer than expected, and both occurred after the consolidated treatment of the right lung. In both cases the issue was wheezing and one of these patients required a short period of non-invasive ventilation. There were no readmissions to hospital for any cause within 30 days of a BT procedure.

**Response to treatment**

As radiofrequency treatment accumulated, a dose-response was evident in ACQ-5 (Fig. 1). Using ANOVA, the overall effect was significant, Wilks’ lambda $p = 0.004$, partial eta squared $0.747$, indicating a strong effect size.

The potential relationship between the radiofrequency treatment administered, and the response in the ACQ-5, was examined in the scatterplot, Fig. 2. The Pearson correlation was $-0.583$, $p < 0.01$. The linear regression line was given by the equation $y = 0.4 - 0.01x$, where $x =$ radiofrequency activations administered and $y =$ change in ACQ-5 from baseline.

The effect of bronchial thermoplasty on lung function (spirometry and static lung volumes), measured at 3 time points, is shown in Table 1. Whilst no effect was observed in spirometry, treatment led to a significant reduction in the gas trapping measures, RV and RV/TLC.

**Imaging**

At baseline, there were minor CT abnormalities detected in 8 of 10 patients. Bronchial wall thickening was reported in 4 cases, mild bronchiectasis in 2 cases and mild emphysema in 3 cases. The mean CT emphysema score, measured as percentage of Hounsfield units with a value less than minus 950 on the inspiratory scan at TLC, was $3.3 \pm 5.0$%. There was no evidence of any new CT abnormalities present on the mid-treatment CT scan.

The validity of the volume measurements made during the imaging studies was tested by comparing the CT

| Table 1 | The effect of bronchial thermoplasty on lung function |
|---------|-----------------------------------------------|
|         | Baseline | Mid treatment | 6w post | $p$       |
| FEV1%predicted | $42.9 \pm 11.5$ | $43.3 \pm 12.3$ | $46.0 \pm 11.9$ | NS       |
| VC % predicted | $72.1 \pm 12.8$ | $74.5 \pm 10.9$ | $79.9 \pm 13.4$ | NS       |
| TLC % predicted | $108.3 \pm 20.7$ | $109.9 \pm 22.0$ | $108.5 \pm 22.0$ | NS       |
| RV % predicted | $158.8 \pm 44.8$ | $160.4 \pm 51.4$ | $148.0 \pm 48$  | < 0.05   |
| RV/TLC ratio % | $56 \pm 10$ | $56 \pm 11$ | $52 \pm 11$ | < 0.05   |

$p$:ANOVA repeated measures

| Table 2 | The effect of bronchial thermoplasty on lobar volumes |
|---------|-----------------------------------------------|
| Lobe (litres) | TLC baseline | TLC Post left Rx | $p$ | FRC baseline | FRC Post left Rx | $p$ |
| Right Upper | $1.04 \pm 0.35$ | $1.04 \pm 0.35$ | ns | $0.78 \pm 0.25$ | $0.78 \pm 0.25$ | ns |
| Right Middle | $0.37 \pm 0.15$ | $0.37 \pm 0.15$ | ns | $0.30 \pm 0.10$ | $0.30 \pm 0.11$ | ns |
| Right Lower | $1.26 \pm 0.40$ | $1.27 \pm 0.40$ | ns | $0.91 \pm 0.26$ | $0.94 \pm 0.27$ | ns |
| Left Upper | $1.24 \pm 0.49$ | $1.19 \pm 0.45$ | < 0.05 | $0.90 \pm 0.36$ | $0.85 \pm 0.36$ | 0.12 |
| Left Lower | $1.03 \pm 1.40$ | $1.07 \pm 2.02$ | ns | $0.77 \pm 0.29$ | $0.77 \pm 0.34$ | ns |
estimated lung volumes at TLC and FRC, with the volumes measured by plethysmography. The Pearson correlation at TLC was \( r = 0.98, p < 0.001 \) and the offset difference between the two techniques (or \( c \) in the linear regression equation \( y = mx + c \)) was \( -0.59 \) l - this difference being explained by the CT studies being performed in the supine position whilst plethysmography was conducted upright. At FRC, the correlation was \( r = 0.95, p < 0.001 \).

**Lobar volumes**

The volumes of the individual lobes of each lung were calculated both at TLC and FRC, and then were compared before and after BT treatment of the left lung (right lung untreated control). The individual lobar volumes are shown in Table 2. A small reduction in lobar volume was evident after treatment of the left upper lobe, but no effect was observed otherwise in either lung.

**Airway luminal volumes**

The low CT density of air was used to identify and reconstruct airways within the lung. Following automated segmentation of the bronchial tree, the airways were manually checked and corrected. The trachea and main bronchi were labelled central airways, being the airways untreated by BT. The lobar and segmental airways, and branches down to 2 mm in diameter were labelled distal airways, being the airways treated by BT as per our study. The validity of the airway volume measurements was tested by comparing the results with a database of age, sex and height matched control values for healthy adults held by FLUIDDA. When compared to the healthy airways, at baseline, asthmatic airways were smaller in volume but similar in order of magnitude: Total Airway Luminal Volume 71.4 ± 11.9% predicted \( (p < 0.05) \).

Increased luminal volume was observed on the treated side in 9 of 10 patients at both TLC and FRC. No change in airway volume was seen in the untreated right side, nor the central airways.

The ratios between the distal airway volume and the lung volume at FRC, pre and post treatment are shown in Table 4. The distal airway volume as a proportion of the lung volume is shown to increase after treatment.

The change in airway volume with full inspiration from FRC was compared in both lungs before and after treatment (Table 5). The data suggests an increase in airway distensibility after treatment, not seen on the control side (Fig. 3).

The potential relationship between the change in luminal airway volume at TLC on the treated left side, and the change in ACQ-5 at the mid treatment evaluation was explored. The Pearson Correlation was \( r = -0.61, p = 0.06 \).

**Airway resistance**

Airway resistance was estimated using computational fluid dynamics (11,12,16) and was reported for each lobe at TLC and FRC, and pre and post treatment of the left side. We were unable to demonstrate a statistically significant effect.

**Additional measurements**

Air trapping was defined as the percentage intrapulmonary voxels ranging between \(-1024\) and \(-850\) Hounsfield units measured in expiration at FRC [20]. No effect was observed following BT. No significant effects of treatment were observed on airway wall volume, nor airway wall area. Blood vessel density was determined by using a density mask of \(-600\) to \(+600\) Hounsfield units applied to the TLC scan. The total estimated blood vessel volume at baseline was \(77.5 ± 46.5\) mls for the right lung and \(68.8 ± 39.7\) for the left lung. No changes were observed after in either value after BT.

**Table 3** The effect of BT on airway luminal volumes

| Airway Volume (mls) | TLC Baseline | TLC Post left Rx | p     | FRC Baseline | FRC Post left Rx | p     |
|---------------------|-------------|-----------------|-------|--------------|-----------------|-------|
| Distal Left side    | 4.8 ± 2.1   | 6.1 ± 3.3       | < 0.05| 2.3 ± 1.0    | 2.7 ± 1.2       | < 0.01|
| Distal Right side   | 5.6 ± 3.3   | 5.8 ± 4.4       | ns    | 2.8 ± 1.5    | 2.7 ± 1.6       | ns    |
| Central airways     | 24.5 ± 8.6  | 24.6 ± 9.9      | ns    | 16.5 ± 6.3   | 17.5 ± 6.4      | ns    |

**Table 4** Ratio of distal airway volume (mls) to lung volume (litres) at FRC

|                | Baseline | Post Left Rx | p     |
|----------------|----------|-------------|-------|
| Left Lung      | 1.48 ± 0.72 | 1.82 ± 1.04 | < 0.05|
| Right Lung     | 1.09 ± 0.43 | 1.08 ± 0.55 | NS    |

p: paired t-test
The most important finding in this study is the demonstration that airway luminal volume substantially increased after BT. This observation provides the pathophysiological missing link between the reduction in airway smooth muscle mass observed in biopsy studies, and the improvement in symptoms observed after treatment. It is a novel observation in humans but is entirely consistent with early canine preclinical studies [21] where one lung was treated by BT, whilst the other served as a control. Following recovery, the dogs were anaesthetised, ventilated and paralysed, and then the lungs were inflated to pre-specified inflation pressures. At each pressure a CT scan was performed, and the airway luminal area determined. The authors demonstrated that for any individual inflation pressure, the airways of the treated lung were significantly larger than on the untreated side [21].

In addition to showing that after BT, airway luminal volume is greater than control at the same level of lung inflation, the current study suggests that the airways may be more distensible after BT. The incremental increase in airway volume as the patient inspires from FRC to TLC is small on the untreated side, but much greater in the treated lung. Reduced airway distensibility is a known feature of the asthmatic airway, ascribed to airway wall remodelling [22, 23]. BT has been shown to reduce the hypertrophied airway smooth muscle layer – a characteristic feature of airway remodelling in severe asthma [24, 25].

It would be anticipated that increased luminal volume would have downstream effects in more distal parts of the lung. This has been modelled by Donovan [26], who has predicted a reopening cascade in distal airways following BT. It would therefore be expected that a deflating effect would be observed in lungs that exhibit marked gas trapping, and, indeed, that was seen in this current study, where both the RV and RV/TLC ratio reduced after treatment. We also have noted this observation previously in a larger series [27]. This effect is also consistent with emerging data from MRI studies showing improvement in ventilation heterogeneity in severe asthma following BT [28]. With the increased luminal airway volume, it would also be expected that a reduction in airway resistance would be observed. We were unable to show this in this study but we believe that this is likely to be due to the small sample size and the large biological variation between patients in this heavily calculated parameter.

The current study also demonstrates, for the first time, a progressive improvement in symptoms as treatment accumulates. This is an important observation because the demonstration of a dose–response relationship to a therapy is one of the Bradford Hill criteria used to assess biological causality, and argues in favour of BT having a physiological effect rather than a placebo effect [29].

### Table 5

| Delta Airway Volume TLC minus FRC (mls) | Baseline | Post Left Rx | Mean change from baseline |
|--------------------------------------|----------|--------------|--------------------------|
| Left lung                            | 2.5 ± 1.3| 3.5 ± 2.5    | 48 ± 79%*                |
| Right Lung                           | 2.8 ± 2.3| 3.1 ± 3.1    | 5 ± 41%                  |

*p < 0.05, paired t-test, left side versus right side
relationship demonstrated between radiofrequency activations delivered, and improvement in symptoms observed, further supports previous work suggesting that a potential reason for non-response to BT is an inadequate quantum of radiofrequency treatment [30].

Despite this being a small study, a trend emerged suggesting that the improvement in symptoms at the mid treatment evaluation was related to the increase in airway volume observed on the treated side. This fits with clinical expectations but will need a larger study to prove. Of the 10 patients in the current study, 9 showed an improvement in ACQ-5 greater than the minimal clinically significant difference at the mid treatment evaluation. The remaining tenth patient, however, showed improvement in FEV1% predicted, Residual Volume and left–sided airway volumes. The treating physician therefore concluded that the patient had responded to therapy, although this had not been reflected in the ACQ-5 score. This demonstrates the perceptual element to the ACQ-5 score. The ability to quantify a change in airway volume with treatment, now provides a potential objective marker of response to therapy which could be a useful tool in future clinical practice.

Conclusion
In this human study, we demonstrate that bronchial thermoplasty increases the luminal airway volume on the treated side compared to the control lung. We suggest that this is the link between the airway smooth muscle atrophy demonstrated pathologically, and the improvement in symptoms observed clinically.

Abbreviations
ACQ-5: Asthma control questionnaire-5 item version; BT: Bronchial thermoplasty; CT: Computed tomography; ERS/ATS: European Respiratory Society/American Thoracic Society; FEV1: Forced expiratory volume in 1 s; FRC: Functional Residual Capacity; RV: Residual Volume; TLC: Total Lung Capacity; VC: Vital capacity

Acknowledgements
The authors would like to thank Peninsula Health and Monash University for supporting this research work.

Authors’ contributions
DL had access to all study data and takes responsibility for data integrity and analysis. DL performed all BT procedures. GS and CB co-ordinated all imaging studies. CB and KB performed pre and post procedure patient assessments. VP and FT assisted with study design and analysis. All authors contributed to manuscript preparation and intellectual input. All authors read and approved the final manuscript.

Funding
D.L. is the recipient of a Monash University post-graduate scholarship.

Availability of data and materials
The data sets analysed in this study are available from the corresponding author upon request.

Ethics approval and consent to participate
Prospective approval for this study was provided by the Peninsula Health Human Research and Ethics Committee. All patients provided written informed consent prior to participation in this study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Thoracic Medicine, Frankston Hospital, Peninsula Health, 2 Hastings Road, Frankston, VIC 3199, Australia. 2Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic, Australia. 3Department of Medical Imaging, Frankston Hospital, Peninsula Health, Frankston, Vic, Australia. 4Department of Respiratory Medicine, Eastern Health, Box Hill, Vic, Australia.

Received: 8 June 2019 Accepted: 10 July 2019
Published online: 16 July 2019

References
1. Global Initiative for Asthma. Global strategy for asthma management and prevention, 2016. Available at www.ginasthma.org
2. Poon AH, Hamid Q. Severe asthma: have we made progress? Ann Am Thorac Soc. 2016;13(suppl 1):S69–77.
3. McDonald V, Hiles S, Jones K, Clark V, Yorke J. Health-related quality of life burden in severe asthma. MJA. 2018;209(2 Suppl):S28–32.
4. Thomson N, Chaudhuri R, Heaney L, Bucknell C, Niven R, Brightling C, Menzies-Gow A, Mansur A, McSharry C. Clinical outcomes and inflammatory biomarkers in current smokers and exsmokers with severe asthma. J Allergy Clin Immunol. 2013;131:1008–16.
5. AH-Muhisien S, Johnson JR, Hamid Q. Remodeling in asthma. J Allergy Clin Immunol. 2011;128:451–62.
6. Chakir J, Hai-Salem I, Gras D, Joubert P, Beaudoin E, Biradel S, Lampron N, Martel S, Chanez P, Boulet L, Laviolette M. Effects of bronchial thermoplasty on airway smooth muscle histopathology and collagen deposition in asthma. Ann Am Thor Soc. 2015;12(11):1612–8.
7. Cox G, Thomson N, Rubin A, Niven R, Conis P, Siersted H, Olivenstein R, Pavord I, McCormack D, Chaudhuri R, Miller J, Laviolette M. Asthma control during the year after bronchial thermoplasty. NEJM. 2007;356:1327–37.
8. Castro M, Rubin A, Laviolette M, Fiterman J, De Andrade Lima M, Shah P, Fiss E, Olivenstein R, Thomson N, Niven R, Pavord R, Simoff M, Duhamel D, McEvoy C, Barbosa R, ten Hacken N, Wechsler M, Holm M, Phillips M, Erzuurn S, Lunn W, Israel E, Jarjour N, Klaft M, Sharifi N, Quiring J, Berry S, Cox G. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma. A multicentre, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010;181:116–24.
9. Chupp G, Laviolette M, Cohn L, McEvoy C, Bansal S, Shifren A, Khatri S, Grubb M, McMillen E, Strauss R, Kline J. Long-term outcomes of bronchial thermoplasty in subjects with severe asthma: a comparison of 3-year follow-up results from two prospective multicenter studies. Eur Respir J. 2017;50:1700117.
10. Pavord I, Cox G, Thomson N, Rubin A, Conis P, Niven R, Chung K, Laviolette M. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med. 2007;176:1185–91.
11. De Backer J, De Backer W. Introduction to Functional Respiratory Imaging (FRI). Belgium: FLUIDDA press; 2017.
12. De Backer JW, Vos WG, Devolder A, Verhulst SL, Gernonpre P, Wuys FL, Parizel PM. De Backer W. Computational fluid dynamics can detect changes in airway resistance in asthmatics after acute bronchodilation. J Biomech. 2008;41(1):106–13.
13. De Backer JW, Vos WG, Vincharuk SC, Claes R, Drollmann A, Wulfank D, Parizel PM, Gernonpre P, De Backer W. Validation of computational fluid dynamics in CT-based airway models with SPECT/CT. Radiology. 2010;257(3):854–62.
14. Tahir BA, Van Holsbeke C, Ireland RH, Swift AJ, Horn FC, Marshall H, Kenworthy JC, Parra-Robles J, Hartley R, Kay R, Brightling CE, De Backer J, Vos W, Wild JM. Comparison of CT-based lobar ventilation with 3He MR imaging ventilation measurements. Radiology. 2016;278(2):585–92.
15. De Backer LA, Vos W, De Backer J, Van Holsbeke C, Vinchurkar S, De Backer W. The acute effect of budesonide/formoterol in COPD: a multi-slice computed tomography and lung function study. Eur Respir J. 2012;40(2): 298–305.

16. De Backer L, Vos W, Salgado R, De Backer J, Develde A, Verhulst S, Claes R, Gromonpepe PR, De Backer WA. Functional imaging using computer methods to compare the effect of salbutamol and ipratropium bromide in patient-specific airway models of COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:337–46.

17. Chung FK, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk P, Adcock I, Bateman E, Bel E, Bleeker E, Boulet LP, Brightling C, Chanez P, Dahlén SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Lass J, Maquard P, Sorkness R, Teague W. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–73.

18. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999; 14:902–7.

19. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, Macintyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. ATS/ERS task force: general considerations for lung function testing. Eur Respir J. 2005;26:153–61.

20. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip M, Zheng J, Stocks J. Multi-ethnic reference values for spirometry for the 3–95 year age range: the Global Lung Function 2012 equations.

21. Brown R, Wizeman W, Danek C, Mitzner W. Effect of bronchial thermoplasty on airway distensibility. Eur Respir J. 2005;26:277–82.

22. Kelly V, Brown N, Sands S, Borg B, King G, Thompson B. Effect of airway smooth muscle tone on airway distensibility measured by the forced oscillation technique in adults with asthma. J Appl Physiol. 2012;112:1494–503.

23. Ward C, Johns D, Bish R, Pais M, Reid D, Ingram C, Felts B, Walters EH. Reduced airway distensibility, fixed airflow limitation, and airway wall remodelling in asthma. AJRCCM. 2001;164(9):1718–21.

24. Pretolani M, Dombret MC, Thabut G, Knap D, Hamidi F, Debray MP, Taille C, Chanez P, Aubier M. Reduction of airway smooth muscle mass by bronchial thermoplasty in patients with severe asthma. Am J Respir Crit Care Med. 2014;190:452–4.

25. Denner D, Doeing D, Hogarth K, Dugan K, Naureckas E, White S. Airway inflammation after bronchial thermoplasty for severe asthma. Ann Am Thor Soc. 2015;12(9):1302–9.

26. Donovan G, Elliot J, Green F, James A, Noble P. Unravelling a clinical paradox: why does bronchial thermoplasty work in asthma? Am J Resp Cell Mol Biol. 2018;59(3):355–62.

27. Langton D, Ing A, Bennett K, Wang W, Farah C, Peters M, Plummer V, Thien F. Bronchial thermoplasty reduces gas trapping in severe asthma. BMC Pulmonary Medicine. 2018;18:155.

28. Thomen R, Shashadri A, Quirk J, Kozlowski J, Ellison H, Szczesniak R, Castro M, Woods J. Regional ventilation changes in severe asthma after bronchial thermoplasty with 1He MR imaging and CT. Radiology. 2015;274:250–9.

29. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295–300.

30. Langton D, Sha J, Ing A, Fielding D, Thien F, Plummer V. Bronchial thermoplasty: activations predict response. Respir Res. 2017;18:134.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.